Showing results (631-640 of 794) with videos related to

Sort By:
Pageof 80
Molecular Cancer Therapeutics|August 28, 2020
Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid TumorsE Gabriela Chiorean, Susan M Perkins, R Matthew Strother, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway TrialFunda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney, et al.
The Prostate|August 2, 2017
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancerLauren C Harshman, Lillian Werner, Abhishek Tripathi, et al.
Clinical Genitourinary Cancer|January 15, 2018
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate CancerEdoardo Francini, Steven Yip, Shubidito Ahmed, et al.
Cancer|November 15, 2018
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancerRana R McKay, Lillian Werner, Susanna J Jacobus, et al.
Brachytherapy|August 17, 2016
Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancerYu-Wei Chen, Vinayak Muralidhar, Brandon A Mahal, et al.
Cancers|August 27, 2021
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate CancerEdoardo Francini, Fang-Shu Ou, Justin Rhoades, et al.
European Urology Oncology|August 19, 2020
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED TrialAlan H Bryce, Yu Hui Chen, Glenn Liu, et al.
Nutrients|November 9, 2024
Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment LengthBenjamin J Behers, Brett M Behers, Christoph A Stephenson-Moe, et al.
JAMA Oncology|February 14, 2020
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate CancerJason W D Hearn, Christopher J Sweeney, Nima Almassi, et al.
Pageof 80